VYVGART is leading the growth of all biologics in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP), proving the power of argenx's approach to redefine treatment paradigms through evidence generation and more effective, convenient medicines. By the end of 2026, the pipeline will include four Phase 3 molecules and a total of 10 molecules in clinical development.
Cyborg Score Rationale
The company demonstrates strong financial health with robust margins, solid balance sheet, current ratio of 5.6 and debt-to-equity ratio of 0.01, indicating strong liquidity and minimal leverage. Rapid revenue growth, expanding patient base, and robust pipeline advancement support strong operational momentum and market positioning.
Top Insights
90% revenue growth to $4.15B in 2025 with 19,000 patients treated demonstrates explosive commercial traction and market adoption.
Two additional FcRn molecules (ARGX-213 and ARGX-124) are advancing with ARGX-213 entering patient studies in 2026 and ARGX-124 completing Phase 1 by end of 2026, enabling pipeline depth.
Four new candidates emerged from the Immunology Innovation Program in 2025, with three additional molecules expected to enter Phase 1 in 2026, supporting goal of launching one new candidate annually.
Leadership transition in progress with Karen Massey becoming CEO and Tim Van Hauwermeiren becoming Chairman, subject to shareholder approval at May 6, 2026 meeting.
Named Competitors
Soliqua — Alternative immunology therapies for autoimmune conditions
Vimizim — Rare disease and immunology biotechnology
Ravulizumab — Complement inhibitor for rare autoimmune disorders
Recent Developments
(January 2026) Reported 2025 sales of $4.15B, 90% year-over-year growth with approximately 19,000 patients globally
(January 2026) Announced four Phase 3 readouts and new pipeline candidates targeted for 2026 including registrational studies in Graves' disease
(January 2026) Leadership transition announced with Karen Massey as incoming CEO and Tim Van Hauwermeiren as incoming Chairman
(December 2025) Established argenx Brazil for expanded Latin American presence
Open the full interactive argenx SE report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.